TG Therapeutics
A commercial stage biopharmaceutical company focused on developing therapies for B-cell diseases, with a current focus on multiple sclerosis.
Last updated September 11, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
TG Therapeutics is a commercial stage biopharmaceutical company. According to its website, it was founded with the goal of leveraging scientific advances to develop treatment options for patients, and today focuses on translating an understanding of B-cells into therapies for autoimmune diseases, with a current focus on multiple sclerosis (MS). Its product BRIUMVI (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis in adults.
History
TG Therapeutics was founded with one goal in mind – to leverage scientific advances to develop the best possible treatment options for patients. Today, its focus is on translating that deep understanding of B-cells into developing therapies for autoimmune diseases, with a current focus on multiple sclerosis (MS).
Products and positioning
BRIUMVI (ublituximab-xiiy)
Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/tg-therapeutics · Editorial policy · How profiles are compiled